Prostate Cancer
Conditions
Keywords
prostate carcinoma, salvage therapy, biochemical relapse
Brief summary
The primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dSRT, i.e., SRT initiated at PSA values of 0.4-0.5 ng/ml) to those of early salvage therapy (eSRT, i.e., at PSA levels of 0.2 ng/ml) in patients with biochemical relapse after radical prostatectomy. The secondary objective of the trial is to perform analysis of the subgroups of patients to determine which patients are most likely to benefit from dSRT Exploratory objective of the trial is to determine whether selected molecular genetic parameters (172 candidate genes and molecular alterations) and known clinical parameters can be used to identify potential predictors of worse prognosis in patients with known risk factors for relapse after radical prostatectomy, thereby augmenting and refining patient stratification, optimizing their therapy, and clarifying the proper timing of multimodal therapy
Interventions
RADIATIONEarly salvage radiotherapy (eSRT)
eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml). 66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy.
RADIATIONDelayed Salvage radiotherapy (dSRT)
dSRT administered if PSA levels increase to ≥ 0.4 ng/ml. 66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy.
Sponsors
General University Hospital, Prague
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A balanced design is used for the 1:1 randomization into two arms A and B:
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \> 18 years of age * Pathologically confirmed invasive prostate carcinoma with minimal 1 risk factor (RF) after radical prostatectomy (RP) * Patient refuses the adjuvant therapy after normalization of urinary function within 6 month after RP * Signed informed consent to participate in the study and (where necessary) consent to participate in the translational part of the research (not a requirement) * ECOG 0 - 1 * pT2 and minimal 1 risk factor (RF): * R1 (PSM), and/or * Gleason score (4+3=7) 8-10 and/or ISUP grade group 3-5 * pT3a /pT3b with or without one RF * No evidence of suspicious pelvic lymph nodes by initial diagnostic: cN0 and/or pN0 * No evidence of suspicious distant metastases by initial diagnostic: M0 * Patient with decline of PSA level to undetectable PSA levels (\< 0,1 ng/ml) or around 0,2ng/ml and with another decreasing trends so that the PSA level decline within 12-24 weeks after RP to undetectable levels (\< 0,1 ng/ml) and with renewed increase of PSA \>0,2 ng/ml (BCR= biochemical relapse) without any clinical relapse on PSMA PET/CT * No hormonal therapy prior and /or after the radical prostatectomy * Patient suitable and fit for subsequent radiotherapy with high likelihood of good compliance to the follow-up
Exclusion criteria
* Life expectancy (based on Charlson comorbidity index) \< 10 years * Patient not fit for the therapy * History of other cancer (other than a radically removed non-melanoma skin carcinoma) * Previous pelvic irradiation * Active immunosuppressive medication * History of hormone therapy prior to randomization * cN1 and/or pN1 and M1 * PSA-persistence after RP (PSA 12-weeks after RP \> 0.1 ng/ml or no decreasing trend described in Inclusion criteria)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival (EFS) | Analysed 3 years after randomisation of the last patient. | Defined as a time to re-documented biochemical relapse after salvage therapy (bRFS), demonstration of clinical relapse (i.e.,local relapse /lRFS/, locoregional relapse /lrRFS/, distant relapse /MFS/) and/or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Carcinoma-specific survival (CSS) | Analysed 5/10 years after randomization of the last patient. | — |
| Overall survival (5y- and 10y- OS) | Analysed 5/10 years after randomization of the last patient. | — |
| Incidence of treatment-related acute and late toxicity | Analysed 5 years after randomization of the last patient. | Comparison of the incidence of treatment-related acute and late toxicity between patients after early/ delayed salvage therapy. Acute and late toxicity will be assessed and graded using Common Terminology Criteria for Adverse Events (CTCAE). |
| Health-related quality of life (QoL) assessment. | Analysed 5 years after randomization of the last patient. | The analysis of the QoL of both study ARMs will be made based on EORTC validated questionnaires (QLQ-C30 and QLQ-PR25). QLQ-C30 was developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. The EORTC QLQ-PR25 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 25 items specifically related to prostate cancer. |
Contacts
Primary ContactSona Argalacsova, MD, PhD
Backup ContactOtakar Capoun, MD, PhD
Outcome results
None listed